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Abstract
Background Acromegaly is an insidious disorder caused
by a pituitary growth hormone (GH)-secreting adenoma
resulting in high circulating levels of GH and insulin-like
growth factor I (IGF-I). Respiratory disorders are common
complications in acromegaly, and can severely impact on
quality of life, eventually affecting mortality.
Objectives The present study aimed to explore structural
and functional lung alterations of acromegalic subjects.
Methods We enrolled 10 consecutive patients (M/F: 5/5)
affected by acromegaly. In all patients, magnetic resonance
imaging (MRI) revealed the presence of pituitary tumor.
All patients underwent clinical, lung functional, biological,
and radiological assessments. Ten healthy age-matched
subjects also served as controls.
Results No statistically significant differences in lung
function were detected between acromegalic and healthy
subjects (p C 0.05 for all analyses). However, the diffusing
capacity for CO (TLCO) was significantly lower in the
acromegalic group than in healthy subjects (TLCO% pre-
dicted: 78.1 ± 16 vs. 90 ± 6 %, respectively, p = 0.04;
KCO% predicted: 77 ± 16 vs. 93 ± 5 %, p = 0.02, re-
spectively). None of the lung function parameters corre-
lated with duration of the disease, or with inflammatory
marker of the airways. In acromegalics, biological (exhaled
NO concentrations) and imaging (total lung volume, TLV,
and mean lung density, MLD) evaluations were within
normal values. The TLV measured by HRCT was
3540 ± 1555 ml in acromegalics, and the MLD was
-711 ± 73 HU. None of the lung functional, radiological,
and biological findings correlated with GH or IGF-I levels,
and no correlation was found with duration of disease.
Conclusions In the current study, lung function evalua-
tion allowed to detect early involvement of lung
parenchyma, as assessed by TLCO and KCO, even in the
absence of parenchymal density alterations of the lung by
HRCT. These findings suggest to routinely include the
carbon monoxide diffusing capacity in the lung function
assessment for an early intervention in acromegaly.
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Introduction
Acromegaly is an insidious disorder caused by a pituitary
growth hormone (GH)-secreting adenoma resulting in high
circulating levels of GH and insulin-like growth factor
(IGF-I) [1]. During the natural course of acromegaly, the
elevated GH and IGF-I levels lead to a wide range of
cardiovascular, respiratory, endocrine, and metabolic co-
morbidities that contribute to significantly enhanced mor-
tality. The goals of therapy in patients with acromegaly are
the elimination of morbidities associated with the disease
and normalization of the increased mortality. Surgery, ra-
diation, and medical treatments are available for lowering
GH and IGF-I hypersecretion, controlling pituitary tumor
mass effects, and improving morbidity, although no single
therapy is comprehensively successful in controlling the
disease and its clinical manifestations, and often multi-
modal therapies are required for disease control through
suppression of GH hypersecretion, reduction of IGF-I
levels, and control of tumor growth [2, 3]. Comorbidities
should be evaluated and treated during acromegaly within
the clinical context, and the reduction in GH and IGF-I
levels is a valuable and accurate marker for improvement
of the comorbidity associated with acromegaly [4].
Respiratory disorders are common complications in
acromegaly, and the mortality rates from respiratory causes
are threefold more common than in the general population
[5]. Deformities of facial bones, edema, and hypertrophy of
the mucosae and pharyngeal and laryngeal cartilages, en-
largement of the tongue and inspiratory collapse of the
hypopharinx, may contribute to respiratory alterations.
Generalized soft-tissue thickening is a well-known feature
of acromegaly and is related to glycosaminoglycan depo-
sition, as well as to increased collagen production by
connective tissue and tissue edema. The sleep apnea syn-
drome (SAS) is the most common respiratory alteration in
acromegalic individuals, affecting 60–70 % of acromegalic
patients and may present as obstructive, central, or mixed
[6]. In addition, acromegalic pneumomegaly is frequently
observed and, as suggested by lung functional studies, it
might be due to an increased number, rather than volume,
of the alveoli, although data are controversial [7, 8]. De-
spite the increase in lung size, however, the single-breath
carbon monoxide transfer coefficient (KCO) appears to be
lower than expected, thus implying parenchymal
alterations.
In the attempt to establish whether, and to what extent,
the lung is involved in acromegaly, the present study aimed
to explore structural and functional lung alterations of
acromegalic subjects. To this aim, clinical, radiological,
biological, and lung functional assessments were
performed.
Material and Methods
Subjects
For the purpose of the study, we enrolled ten consecutive
patients (M/F: 5/5) affected by acromegaly visiting the
Endocrinology Section of the University of Palermo in
2011. Smoker patients or those with already known respi-
ratory diseases were excluded from this study. Ten healthy
age-matched subjects served as controls. They had never
experienced respiratory symptoms consistent with the di-
agnosis of chronic obstructive pulmonary disease (COPD)
or other lung disease, nor had they ever been diagnosed
with COPD or another lung disease by a physician, and
none of them was on any respiratory medication regimen.
Out of the ten patients included in the study, three were
newly diagnosed patients, not receiving any acromegalic
treatment, three were treated with first-line octreotide-long
acting release (20–30 mg every 28 days), 1 with lanreotide
autogel (90 mg every 28 days), 2 with pegvisomant
(10–15 mg/daily), and one patient had recently received
pituitary surgery. In all patients, MRI (magnetic resonance
imaging) scan revealed the presence of a pituitary tumor.
The mean duration of disease was established by patient
interview, patients’ pictures, and onset of osteoarticular
symptoms.
Based on the nadir GH after oral glucose tolerance test
(OGTT) and IGF-1 levels, patients were divided into those
with controlled (No = 5) and those with uncontrolled
(No = 5) acromegaly. Cut-off level for controlled subjects
was 1 lg/l for random GH and 0.4 lg/l after OGTT, to-
gether with IGF-1 in the age-adjusted normal range, with
the exception of patients under pegvisomant treatment, in
whom only IGF-1 levels were considered as parameter of
activity of disease [9]. At the time of hospitalization, all
patients signed an informed consent for the scientific use of
their data. The study was approved by the Institutional
Review Board of the Faculty of Medicine, University of
Palermo, given that the identity of the participants re-
mained anonymous during database analysis.
Study Design
The study included a total of three visits. All enrolled pa-
tients underwent an initial assessment (Visit 1) in which
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body mass index, and systolic and diastolic blood pressures
were measured in the morning. After an overnight fast,
mean fasting plasma GH (at least three blood samples at
30-min intervals) and IGF-I levels were measured. OGTT
was performed in all patients by measuring plasma blood
glucose, insulin levels, and GH every 30 min for 2 h after
75 g oral glucose load. The pulmonary evaluation was
conducted on two days. The first day (Visit 2) included
clinical, biological, and lung function assessments. On a
separate occasion (Visit 3), lung imaging procedures were
carried out. All patients were in stable conditions on study
days.
Clinical and Functional Assessments
Functional assessment included measures of static and
dynamic lung volumes, as well as single-breath diffusing
capacity for CO, which were performed using a fully
computerized water-sealed Stead-Wells spirometer (Baires
System; Biomedin; Padua, Italy). The transfer factor of
the lung for CO (TLCO) and the KCO was measured to
evaluate the extent of lung parenchymal destruction. At
least two determinations of TLCO that were within 5 %
of each other were obtained, and the highest value was
retained for analysis. Measurements were made in ac-
cordance with the European Thoracic Society stan-
dardisation document on lung volume measurements [10].
FEV1% (forced expiratory volume in the 1st second)
predicted and FVC% (forced vital capacity) predicted, as
well as TLC% (total lung capacity) predicted, TLCO%
predicted, and KCO% predicted were calculated and used
for the analysis.
Biological Assessment
Exhaled nitric oxide (FENO) was measured with a stan-
dardized single-breath method using the electrochemical
analyzer (Hypair FENO, Medisoft), which was
calibrated daily. The measurement procedure was con-
sistent with guidelines published by the American Tho-
racic Society/European Respiratory Society [11]. Subjects
were in sitting position during the entire procedure. Each
individual was asked to take a deep inspiration from room
air and, immediately after, to forcefully exhale through
the mouthpiece that was connected to the on-line
analyzer. To determine if subjects maintained a constant
flow-rate during exhalation, a continuous monitoring of
expiratory flow-rate by graphic display on the monitor
screen was used. All samples were acquired in the
morning between 11:00 and 12:00. FENO was obtained as
the mean of three acceptable measurements at the airflow
rate of 50 ml/s.
Imaging Assessment
Each subject underwent high-resolution computerized to-
mography (HRCT), which was performed by spiral com-
puted tomography (multidetector 64 channels equipment,
Philips Medical System, Cleveland, OH), with a setting of
120 kVp, 200 mAs, a 0.9-mm slice thickness, a rotation
time 0.5 s, and a reconstruction interval of 0.45 mm, pitch
0.923, during a single breath and moved caudally. Images
were reconstructed at a window level of—600 Hounsfield
units (HU) and a window width of 1600 HU.
Two radiologists (MB and FC) evaluated the CT scans
independently, excluding any radiological abnormality of
the lung parenchyma. Total lung volume and parenchymal
density on the HRCT scans as an estimate of parenchymal
damage were measured at full inspiration. Total lung vol-
ume was calculated and expressed in cm3. Parenchymal
density was expressed by lung attenuation parameters, such
as mean lung density at FRC, functional residual capacity
(Mean HUexp) and at TLC, total lung capacity (Mean
HUinsp); in addition, the percent of the lung with a low
attenuation volume at TLC (i.e., below -950 HU, LAV)
was measured as an estimate of the degree of emphysema.
Statistical Analysis
Statistical analysis was performed using Statview 5.0
(SAS Institute Inc., Cary, NC, USA). Univariate analysis
and correlation analysis were performed. Data are ex-
pressed as mean ± SD. Significance level was set at
p B 0.05.
Results
The clinical characteristics and endocrine status of the
study subjects are presented in Table 1. Duration of the
disease was 5.5 ± 3.9 yrs (range: 1–11 years). FEV1%
predicted was 115 ± 21 % (mean ± SD, range:
89–156 %), FVC % predicted was 120 ± 21 % (range:
91–162 %), FEV1/FVC was 0.79 ± 0.5 (range: 0.73–0.89),
and TLC predicted was 110 ± 16 % (range: 93–144 %); in
addition, TLCO% predicted was 78.1 ± 16 % (range:
58–111 %) and KCO% predicted equal to 77 ± 16 %
(range: 56–92 %). Finally, FeNO was 12 ± 8 ppb (range:
4–30 ppb). Healthy controls were matched by gender (5
males and 5 females for each group), age (44 ± 13 vs.
52 ± 10 years, p = 0.17), and height (168 ± 9 vs.
169 ± 10 cm, p = 0.85). In healthy controls, FEV1%
predicted was 110 ± 7 % (mean ± SD, range: 99–122 %),
FVC % predicted was 112 ± 7 % (range: 100–123 %),
FEV1/FVC was 0.82 ± 1.3 (range: 0.80–0.84), and TLC
predicted was 105 ± 10 % (range: 90–117 %). TLCO%
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predicted and KCO% predicted were 90 ± 6 % (range:
80–100 %) and 93 ± 5 % (range: 85–101 %), respective-
ly. We did not find statistically significant differences in
lung function between acromegalic and healthy subjects
(p C 0.05 for all analyses). However, TLCO was sig-
nificantly lower in the acromegalic group than in healthy
subjects (TLCO% predicted and KCO% predicted:
p = 0.04 and p = 0.02, respectively). Complete lung
function characteristics of acromegalic and control subjects
are presented in Table 2 and 3, respectively.
When we divided the patients according to the disease
activity, no differences in static and dynamic lung volumes,
as well as diffusing CO capacity, were detected between
patients with controlled and uncontrolled acromegaly
(p [ 0.05 in all comparisons). In addition, none of the lung
function parameters correlated with duration of the disease.
In acromegalic subjects, the total lung volume measured
by HRCT was 3540 ± 1555 ml, the mean lung density was
-711 ± 73 HU, and LAV% total was 6.6 ± 6 %. None of
the imaging parameters differentiated acromegalic from
healthy subjects, or between active and inactive disease.
However, the lung density evaluated by HRCT sig-
nificantly correlated with TLCO% predicted (r = 0.70,
p = 0.03).
Additional investigations were performed in acrome-
galic subjects with the aim to evaluate which factors can
eventually influence the carbon monoxide transfer coeffi-
cient and the diffusing capacity for CO. The alternative
hypothesis that pulmonary hypertension can affect the
current findings was ruled out by normal values obtained
with transthoracic echocardiography. In addition, nocturnal
oxygen monitoring was performed to screen for nocturnal
reduction in oxygen saturation. All but one subject showed
during the recording time an oxygen saturation higher than
90 % (mean value: 94 %).
Discussion
Acromegaly is considered a rare disease in the general
population. However, its impact on morbidity and mortality,
as well as on health service costs, is not trivial. Respiratory
disorders are common complications in acromegaly, and can
severely impact on quality of life, eventually affecting
mortality. Thus, early identification of lung function im-
pairment could contribute to proper management of the
disease. In the current study, lung function evaluation al-
lowed to detect early involvement of lung parenchyma, as
assessed by TLCO and KCO, even in the absence of
parenchymal density alterations of the lung by HRCT.
Studies investigating the involvement of the respiratory
system in acromegaly have primarily focused on the oc-
currence of obstructive sleep apnea, which is a common
disorder in this disease [6]. Other lung abnormalities, such
as larger lungs, were described by Siafakas and colleagues
[12]. Trotman-Dickenson and colleagues [13] assessed
pulmonary function and disease activity in patients with
acromegaly (19 men and 16 women): large lungs occurred
Table 1 Demographic and clinical characteristics of acromegalic subjects
Patient
No.
Gender Age Smoking BMI Duration
of disease
(yearr)
GH mean
baseline
(lg/L)
GH after
oral glucose
load (lg/L)
Mean
IGF-1
(lg/L)
Concomitant
Diseases
GH hypersecretion treatment
1 M 65 F 31.1 10 6.8 3.7 756 Hypertension,
dyslipidemia
Octreotide LAR
20 mg/monthly
2 M 46 N 26.7 1 8 ### 848 Hypertension None (newly diagnosed)
3 F 53 N 37.2 1 3 1 600 Hypertension None (newly diagnosed)
4 M 57 N 34.6 5 3.28 ### 231 Hypertension,
dyslipidemia
Post-surgery
5 F 50 N 26 4 ### ### 722 Hypertension Octreotide 30 mg/monthly,
pegvisomant 15 mg/daily,
cabergoline 1 mg/weekly
6 F 39 N 29.4 6 1.24 0.56 115 Hypothyroidism Lanreotide 90 mg/2 month
7 M 52 N 24.8 11 ### ### 137 None Octreotide 30 mg/monthly,
pegvisomant 10 mg/daily
8 M 41 N 30.5 1 31 26 1049 None None (newly diagnosed)
9 F 48 N 39.4 6 1.6 0.8 273 Hypertension,
dyslipidemia.
Octreotide 30 mg/monthly
10 F 71 N 29 10 1.2 0.8 225 Hypertension,
dyslipidemia
Octreotide 20 mg/monthly
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in 12 patients (34 %) and upper airflow obstruction in 17
patients (50 %). More recently, studies have focused on
structural and functional abnormalities of the lung that may
be linked to the acromegalic-related pathological process-
es. In this respect, a cross-sectional study including 20
acromegalic patients and 20 age-and height-matched con-
trol subjects was conducted with the objective to describe
the abnormalities in lung structure and function [14]. The
main findings in HRCT in acromegalic patients were air
trapping, airway calcification, and bronchiectasis, which
were observed in 60, 40, and 35 % of cases, respectively.
As in our study, there was no significant correlation be-
tween the levels of GH and insulin-like growth factor I
(IGF-I) and lung function. Interestingly, the diffusing ca-
pacity for CO in the two studies was within the normal
range, and not different from healthy subjects. These ob-
servations are in contrast with our findings. As discussed
below, we reasonably excluded parenchymal causes. We
believe that the discrepancy between our and other studies
is only apparent, since the latter showed larger lung vol-
umes than healthy controls, perhaps explaining normal
TLCO values. This is further confirmed by the fact that our
study subjects did not differ in terms of height. Other au-
thors hypothesized that the diffusing capacity is reduced
both in normal and acromegalic subjects with large lungs
[15, 16], as extrapolated by findings of reduced values
associated with increasing height in healthy children,
suggesting greater recruitment of pulmonary vascular bed
at the apexes in the shorter subjects.
It has been accepted that the excess of GH in acromegaly
induces growth of the lungs. However, the mechanism by
which increased lung growth occurs in acromegaly is not
clear, because studies gave contradictory results. In a study
on the possible mechanisms for the increased lung growth in
acromegalic subjects, Brody et al. [8] found increased values
for TLC, normal elastic recoil, and normal specific lung
compliance. The authors found normal values for TLCO and
a reduced KCO, which suggested that the increased size of
the lung in acromegaly resulted from an increase in alveolar
size rather than number, resulting from an alteration of the
elastic properties of the lungs. Alternative hypotheses, such
as the contribution of pulmonary hypertension and the oc-
currence of nocturnal reductions in oxygen saturation, were
reasonably excluded in the current study. Since the reduced
carbon monoxide transfer coefficient and the reduced dif-
fusing capacity cannot be justified by parenchymal density
alterations of the lung by HRCT, we suggest the occurrence
of an alveolar membrane damage or a microvascular damage
in acromegalic subjects. Further studies are needed to test
this hypothesis.
A significant correlation between duration of
acromegaly and lung size was previously demonstrated
[17]. It has been suggested that when duration of disease
exceeds eight years, patients are very likely to develop
abnormalities of lung function either primarily from the
effects of acromegaly on the lung, or due to the associated
cardiovascular and thoracic skeletal abnormalities. More-
over, some studies showed that a decrease in lung size
occurs in patients who develop GH deficiency and thus,
that normal levels of GH are necessary for maintaining
normal lung size during adult life. De Troyer et al. [18]
investigated the pulmonary function in eight patients with
hypopituitarism in order to determine if the lung is affected
by the generalized visceral atrophy of hypopituitarism; six
patients with acromegaly and trophic hormone deficiencies
were studied for comparison. The patients with hypopitu-
itarism, including one with isolated GH deficiency, had a
restrictive type of ventilatory impairment, which could not
be related to neuromuscular impairment or to an abnor-
mality of chest wall mechanics. Donnelly and colleagues
[7] hypothesized that lung size in acromegaly is achieved
through a process of alveolar hyperplasia rather than hy-
pertrophy. They attributed the decrease in KCO due to an
increase in the unperfused capillary bed, which is caused
by the greater perfusion distances and the lower pulmonary
capillary blood volume in the acromegalic lung.
In conclusion, the current findings confirm and extend
previous observations in acromegaly, suggesting that the
lung is largely, and perhaps invariably, involved in this
disease. The lack of a comprehensive histologic evaluation
of the lung from acromegalic patients does not allow to
draw definite conclusions on the amount and quality of
pulmonary involvement in this disease. This approach
could lead to the identification of an alveolar membrane or
microvascular damage, at the level of which the primary
cause of the functional alterations lies. Following this
primary step, the role of smoke or other lung diseases
should be investigated in this population, to estimate to
what extent the natural course of the disease can be af-
fected. On this basis, we propose to routinely incorporate
the carbon monoxide diffusing capacity in the lung func-
tion assessment for a proper management of the disease.
Conflict of interest None.
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